← Leaderboards
Kelvin W Gee
Kadmus Pharmaceuticals, Inc.
$7,277,902
Attributed
$7,869,164
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2006–19$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$7,869,164 · 8
By mechanism
U01$4,372,988 · 3
R01$2,286,832 · 1
R21$1,082,113 · 3
R41$127,231 · 1
Top collaborators
- John H. Mcdonough3 shared
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignReceptorDoseNicotinic ReceptorsAnimal ModelPharmaceutical PreparationsBaseIn VitroLeadModificationBrainPre-ClinicalLaboratoriesRodentAdverse EffectsReceptor FunctionBiological AvailabilityDrug DiscoveryGamma-Aminobutyric AcidOralDrug KineticsLigandsAreaAcute
Grant awards (23)
Pain drugs based on nicotinic receptor subtype antagonists$739,558
R01 · FY2019 · DA · contact PI
Neurosteroids as a standard medical countermeasure for OP poisoning$369,897
U01 · FY2019 · NS · contact PI
Pain drugs based on nicotinic receptor subtype antagonists$756,850
R01 · FY2018 · DA · contact PI
Neurosteroids as a standard medical countermeasure for OP poisoning$378,047
U01 · FY2018 · NS · contact PI
Pain drugs based on nicotinic receptor subtype antagonists$790,424
R01 · FY2017 · DA · contact PI
Neurosteroids as a standard medical countermeasure for OP poisoning$434,581
U01 · FY2017 · NS · contact PI
Development of Dual GABAA and alpah7 Nicotinic Receptor Modulators for AD$366,314
U01 · FY2013 · AG · contact PI
Drug Development$59,159
U01 · FY2013 · MH · contact PI
Development of Dual GABAA and alpah7 Nicotinic Receptor Modulators for AD$420,344
U01 · FY2012 · AG · contact PI
Drug Development$380,722
U01 · FY2012 · MH · contact PI
Development of Dual GABAA and alpah7 Nicotinic Receptor Modulators for AD$468,070
U01 · FY2011 · AG · contact PI
Drug Development$369,149
U01 · FY2011 · MH · contact PI
Development of Dual GABAA and alpah7 Nicotinic Receptor Modulators for AD$495,936
U01 · FY2010 · AG · contact PI
Development of Dual GABAA and alpah7 Nicotinic Receptor Modulators for AD$105,100
U01 · FY2010 · AG · contact PI
Development of Dual GABAA and alpah7 Nicotinic Receptor Modulators for AD$525,669
U01 · FY2009 · AG · contact PI
Non-sedating modulators of GABA-A receptors for anxiety$172,125
R21 · FY2009 · MH · contact PI
Non-sedating modulators of GABA-A receptors for anxiety$177,525
R21 · FY2008 · MH · contact PI
Optimization of allosteric modulators of nicotinic receptors$166,776
R21 · FY2008 · MH · contact PI
Optimization of allosteric modulators of nicotinic receptors$213,916
R21 · FY2007 · MH · contact PI
Dual Allosteric Modulators of GABA-A and Nicotinic Receptors for Alzheimer's Dise$157,333
R21 · FY2007 · AG · contact PI
Dual Allosteric Modulators of GABA-A and Nicotinic Receptors for Alzheimer's Dise$194,438
R21 · FY2006 · AG · contact PI
IDENTIFYING LIGANDS FOR A NOVEL GABAA RECEPTOR SUBTYPE$7,023
R41 · FY2001 · MH
IDENTIFYING LIGANDS FOR A NOVEL GABAA RECEPTOR SUBTYPE$120,208
R41 · FY2000 · MH